Viking Therapeutics Inc (VKTX)

NASDAQ
2.565
+0.015(+0.59%)
  • Volume:
    228,185
  • Day's Range:
    2.555 - 2.675
  • 52 wk Range:
    2.020 - 7.045

VKTX Overview

Prev. Close
2.55
Day's Range
2.555-2.675
Revenue
-
Open
2.58
52 wk Range
2.02-7.045
EPS
-0.762
Volume
228,185
Market Cap
197.86M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
727,992
P/E Ratio
-4.64
Beta
1.38
1-Year Change
-60.65%
Shares Outstanding
76,688,478
Next Earnings Date
Nov 09, 2022
What is your sentiment on Viking Therapeutics Inc?
or
Vote to see community's results!

Viking Therapeutics Inc News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade
  • Viking Therapeutics Misses Q1 EPS by 2c
    • ByInvesting.com-

    Viking Therapeutics (NASDAQ:VKTX) reported Q1 EPS of ($0.21), $0.02 worse than the analyst estimate of ($0.19). At March 31, 2022, Viking held cash, cash equivalents and short-term...

Viking Therapeutics Inc Analysis

Viking Therapeutics Inc Company Profile

Viking Therapeutics Inc Company Profile

Employees
17

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for metabolic and endocrine disorders. The Company's lead clinical program's drug candidate, VK2809, is an orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß). The Company is conducting VOYAGE study, a phase II b clinical trial of VK2809 in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH). It is also developing VK0214, which is also an orally available, tissue and receptor-subtype selective agonist of TRß for X-linked adrenoleukodystrophy (X-ALD), a rare X-linked, inherited neurological disorder characterized by a breakdown in the protective barriers surrounding brain and nerve cells. It is engaged in a phase I b clinical trial of VK0214 in patients with X-ALD. Its other clinical programs include VK5211, an orally available, non-steroidal selective androgen receptor modulator (SARM).

Read More

Analyst Price Target

Average17.556 (+584.43% Upside)
High30
Low10
Price2.565
No. of Analysts9
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell
  • Maybe sell at 9.00. I may just forget I own some of this for awhile.
    0
    • when you see 8.00 again , close the market ..
      1
      • Worthless stocks, down, down, down and again $1,5?
        2
        • Anyone know why Viking is not higher? Is Covid needs and resources and influenc e for a Viking which is not a Covid "player'? This stock should be at least double the current price.
          0
          • Wow what a happy good news
            1
            • This stock's Beta is smashing the price gains do to the MKT fear.This stock is still a good buy.
              0
              • Time to buy!
                1
                • tip ranks says VKTX stock will go up but simply wall street says it will go down. which one is correct?
                  2
                  • whats the news on VKTX, been hard to find any. please help
                    0
                    • whats the news on VKTX, been hard to find any. please help
                      0